Výsledky vyhledávání - James J. Ferguson
- Zobrazuji výsledky 1 - 16 z 16
-
1
Protein Synthesis and Adrenocorticotropin Responsiveness Autor James J. Ferguson
Vydáno 1963Artigo -
2
Photoaffinity Labeling with Cyclic Nucleotides Autor Ross S. Antonoff, James J. Ferguson
Vydáno 1974Artigo -
3
-
4
The Biosynthesis of β-Hydroxy-β-methylglutaryl Coenzyme A in Yeast Autor Harry Rudney, James J. Ferguson
Vydáno 1959Artigo -
5
-
6
THE BIOSYNTHESIS OF MEVALONIC ACID Autor James J. Ferguson, I.F. Durr, Harry Rudney
Vydáno 1959Artigo -
7
The relationships of high energy phosphates, tissue pH, and regional blood flow to diastolic distensibility in the ischemic dog myocardium. Autor Shin‐ichi Momomura, Joanne S. Ingwall, J. Anthony Parker, Peter Sahagian, James J. Ferguson, William Grossman
Vydáno 1985Artigo -
8
-
9
Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Autor S K Yao, J C Ober, Ashok Krishnaswami, James J. Ferguson, H. Vernon Anderson, Paolo Golino, L. Maximilian Buja, J. T. Willerson
Vydáno 1992Artigo -
10
Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery Autor Jan T. Christenson, Marc Cohen, James J. Ferguson, Robert J. Freedman, Michael F. Miller, E. Magnus Ohman, Ramachandra C. Reddy, Gregg W. Stone, Philip Urban
Vydáno 2002Artigo -
11
-
12
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention Autor Keaven M. Anderson, Robert M. Califf, Gregg W. Stone, Franz-Josef Neumann, Gilles Montalescot, Dave P. Miller, James J. Ferguson, James T. Willerson, Harlan F. Weisman, Eric J. Topol
Vydáno 2001Artigo -
13
Pharmacodynamic Efficacy, Clinical Safety, and Outcomes After Prolonged Platelet Glycoprotein IIb/IIIa Receptor Blockade With Oral Xemilofiban Autor Dean J. Kereiakes, Neal S. Kleiman, James J. Ferguson, A.R. Zaki Masud, Thomas M. Broderick, Charles W. Abbottsmith, John Paul Runyon, Linda C. Anderson, Robert J. Anders, Roger J. Dreiling, Gary Hantsbarger, Brian Bryzinski, Eric J. Topol
Vydáno 1998Artigo -
14
Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease Autor Eric J. Topol, Donald Easton, Robert A. Harrington, Pierre Amarenco, Robert M. Califf, Carmen Graffagnino, Stephen M. Davis, H.C. Diener, James J. Ferguson, Desmond J. Fitzgerald, Jeffrey R. Granett, Ashfaq Shuaib, Peter J. Koudstaal, Pierre Théroux, Frans Van de Werf, Kristina N. Sigmon, Karen S. Pieper, Marc Vallée, James T. Willerson
Vydáno 2003Artigo -
15
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial Autor David R. Holmes, Michael P. Savage, J M Lablanche, Lars Grip, P. W. Serruys, Peter J. Fitzgerald, David L. Fischman, Sheldon Goldberg, Jeffrey Brinker, Andreas M. Zeiher, Leonard M. Shapiro, James T. Willerson, Barry R. Davis, James J. Ferguson, Jeffrey J. Popma, Spencer B. King, A. Michael Lincoff, James E. Tcheng, Robert Chan, Jeffrey R. Granett, Marcia Poland
Vydáno 2002Artigo -
16
Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy Autor James J Ferguson, Robert M. Califf, Elliott M. Antman, Marc Cohen, Cindy L. Grines, Shaun Goodman, Dean J. Kereiakes, Anatoly Langer, Kenneth W. Mahaffey, Christopher C. Nessel, Paul W. Armstrong, Álvaro Avezum, Philip E. Aylward, Richard C. Becker, Luigi M. Biasucci, Steven Borzak, Jacques Col, M Frey, E Fry, Dietrich C. Gulba, Sema Güneri, Enrique Gurfinkel, Robert A. Harrington, Judith S. Hochman, Neal S. Kleiman, Martin B. Leon, José Luis López-Sendón, Carl J. Pepine, Witold Rużyłło, Steven R. Steinhubl, Paul S. Teirstein, Luis O. Toro-Figueroa, Harvey D. White
Vydáno 2004Artigo
Vyhledávací nástroje:
Související témata
Medicine
Internal medicine
Cardiology
Biochemistry
Chemistry
Myocardial infarction
Surgery
Anesthesia
Aspirin
Randomized controlled trial
Alternative medicine
Clinical endpoint
Confidence interval
Enzyme
Heparin
Pathology
Percutaneous coronary intervention
Placebo
Abciximab
Activated clotting time
Angioplasty
Biology
Biosynthesis
Conventional PCI
Gene
Hazard ratio
Nitric oxide
Protein biosynthesis
Yeast
Absolute risk reduction